257 related articles for article (PubMed ID: 11950252)
1. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen.
Makarowski W; Zhao WW; Bevirt T; Recker DP
Osteoarthritis Cartilage; 2002 Apr; 10(4):290-6. PubMed ID: 11950252
[TBL] [Abstract][Full Text] [Related]
2. Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis.
Kivitz A; Eisen G; Zhao WW; Bevirt T; Recker DP
J Fam Pract; 2002 Jun; 51(6):530-7. PubMed ID: 12100776
[TBL] [Abstract][Full Text] [Related]
3. Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis.
Rabeneck L; Goldstein JL; Vu A; Mayne TJ; Rublee DA
Am J Gastroenterol; 2005 May; 100(5):1043-50. PubMed ID: 15842577
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of valdecoxib in treating the signs and symptoms of severe rheumatoid arthritis: a 12-week, multicenter, randomized, double-blind, placebo-controlled study.
Gibofsky A; Rodrigues J; Fiechtner J; Berger M; Pan S
Clin Ther; 2007 Jun; 29(6):1071-85. PubMed ID: 17692722
[TBL] [Abstract][Full Text] [Related]
5. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
Bensen WG; Zhao SZ; Burke TA; Zabinski RA; Makuch RW; Maurath CJ; Agrawal NM; Geis GS
J Rheumatol; 2000 Aug; 27(8):1876-83. PubMed ID: 10955327
[TBL] [Abstract][Full Text] [Related]
6. Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial.
Pavelka K; Recker DP; Verburg KM
Rheumatology (Oxford); 2003 Oct; 42(10):1207-15. PubMed ID: 12810937
[TBL] [Abstract][Full Text] [Related]
7. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial.
Bensen WG; Fiechtner JJ; McMillen JI; Zhao WW; Yu SS; Woods EM; Hubbard RC; Isakson PC; Verburg KM; Geis GS
Mayo Clin Proc; 1999 Nov; 74(11):1095-105. PubMed ID: 10560596
[TBL] [Abstract][Full Text] [Related]
8. A comparison of valdecoxib and naproxen in the treatment of rheumatoid arthritis symptoms.
Williams GW; Kivitz AJ; Brown MT; Verburg KM
Clin Ther; 2006 Feb; 28(2):204-21. PubMed ID: 16678642
[TBL] [Abstract][Full Text] [Related]
9. Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo.
Harris SI; Kuss M; Hubbard RC; Goldstein JL
Clin Ther; 2001 Sep; 23(9):1422-8. PubMed ID: 11589257
[TBL] [Abstract][Full Text] [Related]
10. Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.
White WB; Strand V; Roberts R; Whelton A
Am J Ther; 2004; 11(4):244-50. PubMed ID: 15266215
[TBL] [Abstract][Full Text] [Related]
11. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib.
Goldstein JL; Eisen GM; Agrawal N; Stenson WF; Kent JD; Verburg KM
Aliment Pharmacol Ther; 2004 Sep; 20(5):527-38. PubMed ID: 15339324
[TBL] [Abstract][Full Text] [Related]
12. A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 years.
Goldstein JL; Aisenberg J; Lanza F; Schwartz H; Sands GH; Berger MF; Pan S
Clin Ther; 2006 Mar; 28(3):340-51. PubMed ID: 16750449
[TBL] [Abstract][Full Text] [Related]
13. Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis.
Sikes DH; Agrawal NM; Zhao WW; Kent JD; Recker DP; Verburg KM
Eur J Gastroenterol Hepatol; 2002 Oct; 14(10):1101-11. PubMed ID: 12362101
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen.
Bensen W; Weaver A; Espinoza L; Zhao WW; Riley W; Paperiello B; Recker DP
Rheumatology (Oxford); 2002 Sep; 41(9):1008-16. PubMed ID: 12209034
[TBL] [Abstract][Full Text] [Related]
15. Valdecoxib, a COX-2-specific inhibitor, is an efficacious, opioid-sparing analgesic in patients undergoing hip arthroplasty.
Camu F; Beecher T; Recker DP; Verburg KM
Am J Ther; 2002; 9(1):43-51. PubMed ID: 11782819
[TBL] [Abstract][Full Text] [Related]
16. Valdecoxib for treatment of primary dysmenorrhea. A randomized, double-blind comparison with placebo and naproxen.
Daniels SE; Torri S; Desjardins PJ
J Gen Intern Med; 2005 Jan; 20(1):62-7. PubMed ID: 15693930
[TBL] [Abstract][Full Text] [Related]
17. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.
Simon LS; Weaver AL; Graham DY; Kivitz AJ; Lipsky PE; Hubbard RC; Isakson PC; Verburg KM; Yu SS; Zhao WW; Geis GS
JAMA; 1999 Nov; 282(20):1921-8. PubMed ID: 10580457
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of efficacy, safety and tolerability of valdecoxib in osteo-arthritis patients--an Indian study.
Jagtap SA; Lahoti S; Anwaruddin K; Ram S; Ballary C; Desai A
J Indian Med Assoc; 2002 Nov; 100(11):673-4. PubMed ID: 12797647
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy and tolerability of dexibuprofen and celecoxib in the treatment of osteoarthritis of the hip.
Hawel R; Klein G; Singer F; Mayrhofer F; Kähler ST
Int J Clin Pharmacol Ther; 2003 Apr; 41(4):153-64. PubMed ID: 12708604
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis.
Eisen GM; Goldstein JL; Hanna DB; Rublee DA
Aliment Pharmacol Ther; 2005 Mar; 21(5):591-8. PubMed ID: 15740543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
